Loading clinical trials...
Loading clinical trials...
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS IDE
The purpose of the research study is to develop a new, more sensitive, and less invasive test for diagnosing lung cancer at an earlier stage, when it can more easily be cured. The investigators hypothesize that certain genes are expressed differently in current and former smokers who have lung cancer, and this difference in gene expression may be a biomarker for lung cancer.
Allegro Diagnostics is funding this multi-center study to validate and extend a new diagnostic tool measuring global gene expression in airway epithelial cells obtained at routine bronchoscopy in suspect lung cancer patients. The test, which is highly sensitive and specific for lung cancer, measures the levels of expression of genes in cells brushed from the large bronchi during diagnostic bronchoscopy. Similar brushings of epithelial cells from the nose will be analyzed to determine if gene expression in these cells can be used as a screening tool in subjects who may have now or be at risk for developing lung cancer in the future.
Age
21 - No limit years
Sex
ALL
Healthy Volunteers
No
University of Alabama
Birmingham, Alabama, United States
Pulmonary Associates of Arizona
Phoenix, Arizona, United States
University of California- Davis
Sacramento, California, United States
National Jewish Health
Denver, Colorado, United States
Yale Univeristy
New Haven, Connecticut, United States
North Florida/South Georgia VA
Gainesville, Florida, United States
Indiana University
Indianapolis, Indiana, United States
LSU
New Orleans, Louisiana, United States
St. Elizabeth's Medical Center
Boston, Massachusetts, United States
University of Missouri
Columbia, Missouri, United States
Start Date
February 1, 2010
Primary Completion Date
December 1, 2014
Completion Date
February 1, 2015
Last Updated
June 4, 2015
1,331
ACTUAL participants
Biomarker (not used as an intervention)
DEVICE
Lead Sponsor
Allegro Diagnostics, Corp.
Collaborators
NCT07485114
NCT07486219
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07190248